In 1978, twenty-five-year-old Kiran Mazumdar-Shaw came home to Bangalore as one of India's only trained brewmasters, but no brewery would hire her — the industry simply didn't hire women in that role. So she pivoted into a field almost nobody in India was working in yet: industrial biotechnology.
She started Biocon India out of a rented garage with a starting capital of about ten thousand rupees, extracting enzymes with equipment she rigged together herself. Banks routinely refused to give her a business loan — she was young, female, and working in a sector with no track record in the country, a combination lenders considered too risky to bet on.
She kept the company alive on grit and small contracts, teaching herself to recruit and manage a small, mostly male, initially skeptical workforce willing to take orders from a woman in her twenties running her own garage-based lab.
Decades later, Biocon became India's largest biopharmaceutical company, developing affordable insulin and cancer treatments for patients who couldn't access expensive imported drugs, and Mazumdar-Shaw became one of India's richest self-made entrepreneurs — proof that the industry that once wouldn't hire her would eventually be reshaped by her instead.